Trevena, Inc. Announces Pricing of Underwritten Offering of Common Stock

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc. About Zetia (Ezetimibe) (NASDAQ: TRVN), a clinical stage pharmaceutical company, today announced the pricing of an underwritten offering of 6,500,000 shares of its common stock, offered at a price to the public of $9.75 per share. Betapace (Sotalol) without Rx All of the shares of common stock to be sold in the offering are to be sold by Trevena, Inc. Frumil (Amiloride) with no Rx Trevena, Inc. Fcn with no Rx has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of common stock. Buy Menosan () with free prescription The offering is expected to close on or about September 16, 2015, subject to customary closing conditions. Buy Carnosine online Jefferies LLC, Cowen and Company, LLC and Barclays Capital Inc. http://webmd-review.blogspot.com are acting as joint book-runners for the offering. JMP Securities LLC and Needham & Company, LLC are acting as co-managers for the offering. The gross offering size will be approximately $63.4 million, before deducting customary underwriting discounts and commissions and offering expenses. Trevena, Inc. intends to use the net proceeds from the underwritten offering, together with its existing cash and investments: to complete Phase 3 development, submit a new drug application, and begin launch preparations for TRV130; to complete its Phase 2b BLAST-AHF study for TRV027; to complete initial Phase 1 studies for TRV250; to continue drug discovery in new therapy areas; and for working capital and general corporate purposes. The securities described above are being offered pursuant to a shelf registration statement (File No. 333-203230) that was filed with the United States Securities and Exchange Commission (“SEC”) on April 3, 2015 and that was declared effective by the SEC on April 14, 2015. The securities described above have not been qualified under any state blue sky laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The offering can be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at .sec.gov. A final prospectus supplement will be filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus, when available, may also be obtained by request at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 821-7388, e-mail: Prospectus_Department@Jefferies.com; at Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, telephone: (631) 274-2806; and at Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 888-603-5847, email: Barclaysprospectus@broadridge.com. Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for Trevena, Inc., including statements about Trevena’s anticipated public offering, anticipated use of proceeds and plans and prospects for Trevena and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, uncertainties inherent in the initiation of future clinical trials and such other factors as are set forth in the risk factors detailed in Trevena’s Annual Report on Form 10-K filed with the SEC on March 18, 2015 and the preliminary prospectus supplement filed with the SEC on September 10, 2015 under the heading “Risk Factors.” In addition, the forward-looking statements included in this press release represent Trevena’s views as of the date hereof. Trevena anticipates that subsequent events and developments will cause Trevena’s views to change. However, while Trevena may elect to update these forward-looking statements at some point in the future, Trevena specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Trevena’s views as of any date subsequent to the date hereof.

Seasonal Allergic Rhinitis Pipeline Review 2015 - 9 Companies & 10 Drug Profiles

. Buy Bones online Suminat (Sumatriptan) with free prescription DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/tmjv2f/seasonal_allergic) has announced the addition of the "Seasonal Allergic Rhinitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Seasonal Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. http://pharmaceutical-journal.blogspot.com About Estriol About Vantin (Cefpodoxime) with no prescription It also reviews key players involved in the therapeutic development for Seasonal Allergic Rhinitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Buy Orlistat (Orlistat) with free Rx Buy Ciloxan (Ciprofloxacin) with free Rx It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development Adamis Pharmaceuticals Corporation FAES Farma SA GlaxoSmithKline Plc Glenmark Pharmaceuticals Ltd. Merck & Co., Inc. Mitsubishi Tanabe Pharma Corporation Ono Pharmaceutical Co., Ltd. Shionogi & Co., Ltd. VentiRx Pharmaceuticals, Inc. Drug Profiles (azelastine hydrochloride + mometasone furoate) APC-3000 bepotastine besylate bilastine desloratadine GSP-301 levocabastine hydrochloride ONO-4053 S-555739 VTX-1463 For more information visit .researchandmarkets.com/research/tmjv2f/seasonal_allergic